Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Dynavax Technologies Corp. (NASDAQ: DVAX) closed at $11.34 up 1.16% from its previous closing price of $11.21. In other words, the price has increased by $1.16 from its previous closing price. On the day, 1.2 million shares were traded. DVAX stock price reached its highest trading level at $11.4 during the session, while it also had its lowest trading level at $11.25.
Ratios:
For a deeper understanding of Dynavax Technologies Corp.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.00 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.36. For the most recent quarter (mrq), Quick Ratio is recorded 12.96 and its Current Ratio is at 13.81. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.41.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on February 01, 2024, initiated with a Neutral rating and assigned the stock a target price of $20.
On September 27, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 01 ’24 when Burgess Justin sold 20,526 shares for $12.78 per share. The transaction valued at 262,322 led to the insider holds 0 shares of the business.
Janssen Robert sold 1,500 shares of DVAX for $22,500 on Jan 04 ’24. The SVP and CMO now owns 49,925 shares after completing the transaction at $15.00 per share. On Jan 02 ’24, another insider, Novack David F, who serves as the President & COO of the company, sold 9,000 shares for $14.45 each. As a result, the insider received 130,050 and left with 3,187 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DVAX now has a Market Capitalization of 1483986432 and an Enterprise Value of 995783488. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.38 while its Price-to-Book (P/B) ratio in mrq is 2.36. Its current Enterprise Value per Revenue stands at 4.287 whereas that against EBITDA is -38.139.
Stock Price History:
The Beta on a monthly basis for DVAX is 1.30, which has changed by 0.09990299 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, DVAX has reached a high of $15.15, while it has fallen to a 52-week low of $10.06. The 50-Day Moving Average of the stock is -7.26%, while the 200-Day Moving Average is calculated to be -16.05%.
Shares Statistics:
For the past three months, DVAX has traded an average of 1.97M shares per day and 2651160 over the past ten days. A total of 130.62M shares are outstanding, with a floating share count of 130.21M. Insiders hold about 0.31% of the company’s shares, while institutions hold 96.83% stake in the company. Shares short for DVAX as of 1713139200 were 18536992 with a Short Ratio of 9.41, compared to 1710460800 on 17348223. Therefore, it implies a Short% of Shares Outstanding of 18536992 and a Short% of Float of 17.31.
Earnings Estimates
Dynavax Technologies Corp. (DVAX) is presently subject to a detailed evaluation by 4.0 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$0.02 for the current quarter, with a high estimate of $0.01 and a low estimate of -$0.06, while EPS last year was -$0.19. The consensus estimate for the next quarter is $0.09, with high estimates of $0.11 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.35 and $0.15 for the fiscal current year, implying an average EPS of $0.25. EPS for the following year is $0.5, with 5.0 analysts recommending between $0.74 and $0.29.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $54.97M this quarter.It ranges from a high estimate of $58.44M to a low estimate of $50.71M. As of the current estimate, Dynavax Technologies Corp.’s year-ago sales were $38.59MFor the next quarter, 4 analysts are estimating revenue of $78.37M. There is a high estimate of $80M for the next quarter, whereas the lowest estimate is $76.33M.
A total of 5 analysts have provided revenue estimates for DVAX’s current fiscal year. The highest revenue estimate was $301.07M, while the lowest revenue estimate was $273.1M, resulting in an average revenue estimate of $287.96M. In the same quarter a year ago, actual revenue was $232.28MBased on 5 analysts’ estimates, the company’s revenue will be $347.37M in the next fiscal year. The high estimate is $376.34M and the low estimate is $314.02M.
